TY - JOUR T1 - Major Metabolic Pathway for <em>N</em>-Methyl-2-Pyrrolidone in Humans JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 267 LP - 269 VL - 25 IS - 2 AU - Bengt Åkesson AU - Bo A. g. Jönsson Y1 - 1997/02/01 UR - http://dmd.aspetjournals.org/content/25/2/267.abstract N2 - The aim was to study the metabolic pathway forN-methyl-2-pyrrolidone (NMP) in humans. Three healthy male volunteers were administered 100 mg NMP orally. All urine was collected during nine consecutive days. The identification and quantification of the metabolites were performed by gas chromatography/mass spectrometry (GC/MS). NMP, 5-hydroxy-N-methyl-2-pyrrolidone (5-HNMP),N-methylsuccinimide (MSI), and 2-hydroxy-N-methylsuccinimide (2-HMSI) were found in urine. The mean excreted fractions for NMP, 5-HNMP, MSI, and 2-HMSI were 0.8%, 44%, 0.4%, and 20%, respectively. There was no conjugation with glucoronic acid or sulfate or either 5-HNMP or 2-HMSI. One-third of the orally dosed NMP was not recovered in urine as either NMP, 5-HNMP, MSI, or 2-HMSI. The half-lives for 5-HNMP, MSI, and 2-HMSI in urine were approximateley 4, 8, and 17 hr, respectively. The American Society for Pharmacology and Experimental Therapeutics ER -